Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

NCT06551116 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06551116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06551116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Recruiting
Start date
October 10, 2024
Completion date
September 1, 2029
Enrollment
200 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer